UniQure to Seek FDA Approval to Market Huntington's Disease Drug

Dow Jones06-17 19:41

By Dean Seal

UniQure said it plans to apply for regulatory approval to market one of its primary investigational gene therapies as a treatment for Huntington's disease.

During a recent meeting with the Food and Drug Administration, the agency told the company that a three-year analysis from a study of UniQure's AMT-130 drug would be acceptable as the primary basis for a Biologics License Application to accelerate approval of the drug in Huntington's disease, UniQure said.

The FDA is also seeking to align on the design of a confirmatiory study prior to the submission of the application, the company said.

UniQure said it is committed to conducting the confirmatory study without delay and expects to align with the FDA on the details. It aims to submit the application in the third quarter of this year.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 17, 2026 07:41 ET (11:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644272743?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644272743","market":"sg","top_or_hot":-1,"title":"UniQure to Seek FDA Approval to Market Huntington's Disease Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UniQure said it plans to apply for regulatory approval to market one of its primary investigational gene therapies as a treatment for Huntington's disease. \n</p>\n<p>\n  During a recent meeting with the Food and Drug Administration, the agency told the company that a three-year analysis from a study of UniQure's AMT-130 drug would be acceptable as the primary basis for a Biologics License Application to accelerate approval of the drug in Huntington's disease, UniQure said. \n</p>\n<p>\n  The FDA is also seeking to align on the design of a confirmatiory study prior to the submission of the application, the company said. \n</p>\n<p>\n  UniQure said it is committed to conducting the confirmatory study without delay and expects to align with the FDA on the details. It aims to submit the application in the third quarter of this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 17, 2026 07:41 ET (11:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure to Seek FDA Approval to Market Huntington's Disease Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure to Seek FDA Approval to Market Huntington's Disease Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-17 19:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UniQure said it plans to apply for regulatory approval to market one of its primary investigational gene therapies as a treatment for Huntington's disease. \n</p>\n<p>\n  During a recent meeting with the Food and Drug Administration, the agency told the company that a three-year analysis from a study of UniQure's AMT-130 drug would be acceptable as the primary basis for a Biologics License Application to accelerate approval of the drug in Huntington's disease, UniQure said. \n</p>\n<p>\n  The FDA is also seeking to align on the design of a confirmatiory study prior to the submission of the application, the company said. \n</p>\n<p>\n  UniQure said it is committed to conducting the confirmatory study without delay and expects to align with the FDA on the details. It aims to submit the application in the third quarter of this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 17, 2026 07:41 ET (11:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2644272743","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644272743","pubTimestamp":1781696460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"UniQure said it plans to apply for regulatory approval to market one of its primary investigational gene therapies as a treatment for Huntington's disease.During a recent meeting with the Food and Drug Administration, the agency told the company that a three-year analysis from a study of UniQure's AMT-130 drug would be acceptable as the primary basis for a Biologics License Application to accelerate approval of the drug in Huntington's disease, UniQure said.The FDA is also seeking to align on the design of a confirmatiory study prior to the submission of the application, the company said.UniQure said it is committed to conducting the confirmatory study without delay and expects to align with the FDA on the details. It aims to submit the application in the third quarter of this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","QURE":"uniQure N.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"UniQure将寻求FDA批准上市亨廷顿舞蹈症药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":0.9,"LABU":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  UniQure said it plans to apply for regulatory approval to market one of its primary investigational gene therapies as a treatment for Huntington's disease. \n\n\n  During a recent meeting with the Food and Drug Administration, the agency told the company that a three-year analysis from a study of UniQure's AMT-130 drug would be acceptable as the primary basis for a Biologics License Application to accelerate approval of the drug in Huntington's disease, UniQure said. \n\n\n  The FDA is also seeking to align on the design of a confirmatiory study prior to the submission of the application, the company said. \n\n\n  UniQure said it is committed to conducting the confirmatory study without delay and expects to align with the FDA on the details. It aims to submit the application in the third quarter of this year. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 07:41 ET (11:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644272743","isCrawlerRequest":true}